Flex Pharma Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Flex Pharma (FLKS) PT Lowered to $8 at Jefferies; HotShot Sales Impacted by Seasonality
May 4, 2017 8:19 AM EDTJefferies lowered its price target on Flex Pharma (NASDAQ: FLKS) to $8.00 (from $9.00) while maintaining a Buy rating.
Analyst Matthew Andrews notes HotShot sales were affected by seasonality as expected though there are signals that Q2 is off to a good start.
The firm cut FY 2017 EPS from ($1.90) to ($2.13)
... More